Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics has successfully raised $6.6 million through a two-tranche placement, supported by institutional and professional investors, to advance its clinical trial pipeline. The funds will primarily support the progression of the CHM CDH17 CAR-T and CORE-NK clinical trials, enhancing the company’s ability to reach key clinical milestones and potentially strengthen its market position.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical-stage cell therapy company dedicated to advancing innovative cell therapies for cancer patients. The company focuses on the discovery, development, and commercialization of pioneering cell therapies, including autologous CAR-T and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology disease areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
Learn more about CHM stock on TipRanks’ Stock Analysis page.